Pancreatic Cancer Research

ResearcherDalian Medical UniversityActive in the last 2 years

Dong Shang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2768-5244; OpenAlex author ID A5076654526. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
59
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 1 paper · 2023: 3 papers · 2024: 5 papers · 2025: 4 papers · 2026: 4 papers

Papers 23

  1. Correction: Molecular mechanisms of RACK1-driven metastasis in pancreatic ductal adenocarcinoma revealed by single-cell RNA sequencing. Co-author DOI 10.1007/s12672-026-05467-2↗
  2. Liquid biopsy for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-026-04625-x↗
  3. Author Correction: Liquid biopsy for early detection of pancreatic ductal adenocarcinoma Co-author DOI 10.1038/s41591-026-04775-y↗
  4. Commentary on "Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells". First author DOI 10.1186/s12943-026-02656-z↗
  5. Molecular mechanisms of RACK1-driven metastasis in pancreatic ductal adenocarcinoma revealed by single-cell RNA sequencing. Co-author DOI 10.1007/s12672-025-03679-6↗
  6. Broussoflavonol B induces S-phase arrest and apoptosis in pancreatic cancer cells by modulating the cell cycle checkpoint through inhibition of the AURKA/PLK1 … Co-author DOI 10.1186/s12935-025-03717-x↗
  7. The Molecular Characteristics and Therapeutic Implications of O-glycan Synthesis in Pancreatic Cancer by Integrating Transcriptome and Single-cell Data. Last author DOI 10.2174/0109298673293445240409060446↗
  8. Multi-Omics Profiling Reveals Glycerolipid Metabolism-Associated Molecular Subtypes and Identifies ALDH2 as a Prognostic Biomarker in Pancreatic Cancer. Last author DOI 10.3390/metabo15030207↗
  9. Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.110027↗
  10. Carfilzomib relieves pancreatitis-initiated pancreatic ductal adenocarcinoma by inhibiting high-temperature requirement protein A1. Co-author DOI 10.1038/s41420-024-01806-w↗
  11. Botanical drugs and their natural compounds: a neglected treasury for inhibiting the carcinogenesis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/13880209.2024.2421759↗
  12. A stumbling block in pancreatic cancer treatment: drug resistance signaling networks. Last author DOI 10.3389/fcell.2024.1462808↗
  13. Prospect of Gold Nanoparticles in Pancreatic Cancer. Co-author DOI 10.3390/pharmaceutics16060806↗
  14. Identifying endoplasmic reticulum stress-related molecular subtypes and prognostic model for predicting the immune landscape and therapy response in pancreatic… Last author DOI 10.18632/aging.205094↗
  15. PANoptosis-related molecular subtype and prognostic model associated with the immune microenvironment and individualized therapy in pancreatic cancer. Last author DOI 10.3389/fonc.2023.1217654↗
  16. Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer. Last author DOI 10.3389/fonc.2023.1227606↗
  17. Contributions and prognostic performances of m7G RNA regulators in pancreatic adenocarcinoma. Last author DOI 10.1097/cm9.0000000000002179↗
  18. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. Co-author DOI 10.1016/j.phrs.2021.105595↗
  19. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma. Last author DOI 10.1080/21655979.2021.1933868↗
  20. Circulating leptin and adiponectin levels in patients with pancreatic cancer. Last author DOI 10.1097/cm9.0000000000001509↗
  21. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Net… Last author DOI 10.3389/fgene.2021.692953↗
  22. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-020-01151-3↗
  23. One Distinctive Presentation in Radiology of Pancreatic Cancer: A Rare Case Report. Last author DOI 10.1089/pancan.2017.0009↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Biao Zhang · 8 shared papers, 2021–2026 · strength 2.31
  2. Qihang Yuan · 6 shared papers, 2021–2025 · strength 1.10
  3. Huiyi Song · 3 shared papers, 2023–2026 · strength 0.85
  4. Xu Chen · 4 shared papers, 2021–2023 · strength 0.70
  5. Hong Xiang · 3 shared papers, 2021–2024 · strength 0.67
  6. Hangyu Liu · 2 shared papers, 2025–2026 · strength 0.66
  7. Fangyue Guo · 3 shared papers, 2023–2024 · strength 0.64
  8. Shilin Xia · 3 shared papers, 2023–2025 · strength 0.63
  9. Jifeng Liu · 2 shared papers, 2025 · strength 0.52
  10. Shuang Li · 3 shared papers, 2021–2023 · strength 0.49
  11. Dawei Deng · 2 shared papers, 2021–2025 · strength 0.43
  12. Zhizhou Wang · 2 shared papers, 2021–2024 · strength 0.40
  13. John S. Bolton · 2 shared papers, 2026 · strength 0.39
  14. Caiming Xu · 2 shared papers, 2026 · strength 0.39
  15. Mitsuro Kanda · 2 shared papers, 2026 · strength 0.39
  16. Derek Cridebring · 2 shared papers, 2026 · strength 0.39
  17. Laleh Golkar Melstrom · 2 shared papers, 2026 · strength 0.39
  18. Eunsung Jun · 2 shared papers, 2026 · strength 0.39
  19. Giulia Martina Cavestro · 2 shared papers, 2026 · strength 0.39
  20. Carlos Roberto Becerra · 2 shared papers, 2026 · strength 0.39
  21. Douglas B. Evans · 2 shared papers, 2026 · strength 0.39
  22. Haiyong Han · 2 shared papers, 2026 · strength 0.39
  23. David L. Bartlett · 2 shared papers, 2026 · strength 0.39
  24. Vincent M. Chung · 2 shared papers, 2026 · strength 0.39
  25. Alessandro Mannucci · 2 shared papers, 2026 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.